FDA Approves First Ever RSV Vaccine by GSK
May 5, 2023
For the first time ever, a vaccine for respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration (FDA). GSK’s vaccine, named Arexvy, is now approved for adults over 60 years of age based on strong data showing it reduced infections and severe cases of the disease. The move comes as an RSV candidate from Pfizer faces an imminent decision.
According to Andrew Dunn, “Later this month, the agency is set to make an approval decision on Pfizer’s competing RSV vaccine. That will be followed by a CDC advisory committee that’s expected to weigh in on both shots in June — a decision that could pave the way for shots being available before the next RSV season starts this fall.”
To read more, click here.
(Source: Endpoints News, May 3rd, 2023)
